Spending on medicines as a result of litigation against health authorities is soaring in Brazil. Scrip investigates the challenges firms may face in future, including greater pricing pressure, a more NICE-like health technology appraisal system and increased scrutiny over any perceived industry wrongdoing.
Sub-Saharan Africa has been firmly in the regulatory spotlight over the past year or so, with east and west Africa making progress on projects to speed up drug regulatory procedures through greater cooperation and information sharing at the regional level.
Celltrion and Samsung Bioepis are moving fast to grab leading positions in the global biosimilars space, but how have these two firms got to where there are now? Scrip takes a look at what is driving their success and where they are heading next.
Anil Koul, part of the Johnson & Johnson team that discovered and developed TB drug Sirturo, is currently on a sabbatical to head up IMTECH, an Indian R&D institute. Koul shares with Scrip the ups and downs of Sirturo's development journey and outlines what he hopes to achieve at IMTECH.
CEOs of top Indian firms continue to earn more than their peers at leading multinational firms operating in the country and experts see limited prospects for a major change in pay structures at foreign firms, at least for now. Scrip brings you a snap-shot of CEO earnings at some leading Indian and foreign firms in 2016-17.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.